Abstract
Background: Abdominal aortic aneurysms (AAA) are life-threatening because of the potential for rupture, resulting in death. The current standard treatment for AAA is surgery, comprising laparotomic graft replacement and endovascular repair. However, because surgery carries the risk of major complications and re-intervention, drug therapies are desirable because they may reduce the occurrence of enlargement and rupture.
Objective: Recent research shows that the progression of AAA is related to inflammatory reactions, especially those in the NF-κB pathway. Omega-3 polyunsaturated fatty acids (PUFA) show antiinflammatory effects. Some derivatives of omega-3 PUFA are known as specialized pro-resolving lipid mediators (SPM) such as resolvins. They play an important role in resolving inflammation.
Conclusion: Omega-3 PUFA and SPM may show promised effects for drug treatment of AAA.
Keywords: Abdominal aortic aneurysm (AAA), drug therapy, inflammation, omega-3 polyunsaturated fatty acid (PUFA), resolvin, intraluminal thrombus.
Current Drug Targets
Title:Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives
Volume: 19 Issue: 11
Author(s): Daisuke Akagi*, Katsuyuki Hoshina, Toshiaki Watanabe and Micheal S. Conte
Affiliation:
- Division of Vascular and Endovascular Surgery, Department of Surgery, Cardiovascular Research Institute, University of California, San Francisco CA 94117,United States
Keywords: Abdominal aortic aneurysm (AAA), drug therapy, inflammation, omega-3 polyunsaturated fatty acid (PUFA), resolvin, intraluminal thrombus.
Abstract: Background: Abdominal aortic aneurysms (AAA) are life-threatening because of the potential for rupture, resulting in death. The current standard treatment for AAA is surgery, comprising laparotomic graft replacement and endovascular repair. However, because surgery carries the risk of major complications and re-intervention, drug therapies are desirable because they may reduce the occurrence of enlargement and rupture.
Objective: Recent research shows that the progression of AAA is related to inflammatory reactions, especially those in the NF-κB pathway. Omega-3 polyunsaturated fatty acids (PUFA) show antiinflammatory effects. Some derivatives of omega-3 PUFA are known as specialized pro-resolving lipid mediators (SPM) such as resolvins. They play an important role in resolving inflammation.
Conclusion: Omega-3 PUFA and SPM may show promised effects for drug treatment of AAA.
Export Options
About this article
Cite this article as:
Akagi Daisuke *, Hoshina Katsuyuki , Watanabe Toshiaki and Conte S. Micheal, Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives, Current Drug Targets 2018; 19 (11) . https://dx.doi.org/10.2174/1389450118666171013101815
DOI https://dx.doi.org/10.2174/1389450118666171013101815 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stereotactic Body Radiotherapy in the Management of Head and Neck Malignancies
Current Cancer Therapy Reviews Cerebrovascular Ultrasonography for Selecting Patients for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Clinical Characteristics of Behcet’s Disease in 453 Egyptian Patients Suffering from Uveitis with Gender Comparison
Current Rheumatology Reviews Gauzoma in A Scleroderma Patient Following Open Heart Surgery: A Case Report
Current Rheumatology Reviews Endovascular Therapies for Type B Aortic Dissection
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Potential of Cannabinoids in Trigeminal Neuralgia
Current Drug Targets - CNS & Neurological Disorders Primary Tumors of the Sacrum: Imaging Findings
Current Medical Imaging Heparin Induced Thrombocytopenia: Pathogenetic, Clinical, Diagnostic and Therapeutic Aspects
Cardiovascular & Hematological Disorders-Drug Targets Multimodality Imaging for Interventional Cardiology
Current Pharmaceutical Design A Direct Correlation between Red Blood Cell Indices and Cognitive Impairment After Aneurysmal Subarachnoid Hemorrhage (aSAH)
Current Neurovascular Research A Variant in the Endoglin Gene is Associated with the Development of Sporadic Intracranial Aneurysms
Current Neurovascular Research Currently Used Biologic Agents in the Management of Behcet’s Syndrome
Current Medicinal Chemistry Invasive Aspergillosis in Children and Adolescents
Current Pharmaceutical Design Cardiovascular Magnetic Resonance T2-weighted Imaging of Myocardial Edema in Acute Myocardial Infarction
Recent Patents on Cardiovascular Drug Discovery Efficacy, Duration and Timing of Withdrawal of Prophylactic Treatment with Antiepileptic Drugs in Neurosurgical Conditions
Current Pharmaceutical Design The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Pyridinoline, A Collagen Crosslink, As a Biochemical Marker for Arthritis
Current Rheumatology Reviews Mass Spectrometric Analysis of F2-Isoprostanes: Markers and Mediators in Human Disease
Current Pharmaceutical Analysis Clinical and Imaging Features of Tumors in the Scapula
Current Medical Imaging Rashes, Sniffles, and Stroke: A Role for Infection in Ischemic Stroke of Childhood
Infectious Disorders - Drug Targets